PL2932264T3 - Nowe niezależne od MHC antygeny powiązane z nowotworem - Google Patents

Nowe niezależne od MHC antygeny powiązane z nowotworem

Info

Publication number
PL2932264T3
PL2932264T3 PL13818713T PL13818713T PL2932264T3 PL 2932264 T3 PL2932264 T3 PL 2932264T3 PL 13818713 T PL13818713 T PL 13818713T PL 13818713 T PL13818713 T PL 13818713T PL 2932264 T3 PL2932264 T3 PL 2932264T3
Authority
PL
Poland
Prior art keywords
associated antigens
independent tumor
novel mhc
mhc
novel
Prior art date
Application number
PL13818713T
Other languages
English (en)
Inventor
Dirk Schadendorf
Anette PASCHEN
Silke LÜBCKE
Martina Fatho
Daniela Eberts
Hakim ECHCHANNAOUI
Volker Lennerz
Catherine WÖLFEL
Thomas Wölfel
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of PL2932264T3 publication Critical patent/PL2932264T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL13818713T 2012-12-14 2013-12-16 Nowe niezależne od MHC antygeny powiązane z nowotworem PL2932264T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197289 2012-12-14
EP13818713.3A EP2932264B1 (en) 2012-12-14 2013-12-16 Novel mhc-independent tumor-associated antigens
PCT/EP2013/076760 WO2014091034A1 (en) 2012-12-14 2013-12-16 Novel mhc-independent tumor-associated antigens

Publications (1)

Publication Number Publication Date
PL2932264T3 true PL2932264T3 (pl) 2019-09-30

Family

ID=47355928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13818713T PL2932264T3 (pl) 2012-12-14 2013-12-16 Nowe niezależne od MHC antygeny powiązane z nowotworem

Country Status (13)

Country Link
US (2) US9861688B2 (pl)
EP (1) EP2932264B1 (pl)
JP (1) JP6475166B2 (pl)
AU (2) AU2013357239B2 (pl)
CA (2) CA2894966C (pl)
DK (1) DK2932264T3 (pl)
ES (1) ES2721159T3 (pl)
HU (1) HUE042967T2 (pl)
PL (1) PL2932264T3 (pl)
PT (1) PT2932264T (pl)
SI (1) SI2932264T1 (pl)
TR (1) TR201905447T4 (pl)
WO (1) WO2014091034A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022367B1 (pt) 2013-03-15 2021-06-22 The Trustees Of The University Of Pennsylvania Vacina, molécula de ácido nucleico, e, molécula de aminoácido
JP7013240B2 (ja) * 2015-02-16 2022-01-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９～３７７位エピトープに特異的な完全ヒトＴ細胞受容体
AU2019216982B2 (en) * 2018-02-11 2024-07-04 Memorial Sloan-Kettering Cancer Center Non-HLA restricted T cell receptors and uses thereof
CA3196544A1 (en) * 2020-10-27 2022-05-05 Ying Q. LIN Recombinant t-cell receptors that bind the ny-eso-1 and/or lage-1a cancer antigens
US20240425563A1 (en) * 2021-01-13 2024-12-26 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
MX2024001179A (es) * 2021-07-27 2024-02-27 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45.
EP4527849A1 (en) 2023-09-19 2025-03-26 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hla-independent antigen binders, such as t-cell receptors, against pd-l1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3267966B2 (ja) * 1989-08-11 2002-03-25 アムラド・コーポレイション・リミテッド 顆粒球―マクロファージコロニー刺激因子受容体およびその誘導体における改良
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2004528823A (ja) * 2000-10-31 2004-09-24 ディアデクサス インコーポレーテッド 大腸特異的遺伝子およびタンパク質に関する組成物および方法
CA2647449C (en) 2006-03-27 2017-05-16 Medimmune Limited Binding member for gm-csf receptor
PT2016102E (pt) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
AU2007314164B2 (en) * 2006-11-03 2013-05-02 Central Adelaide Local Health Network Inc Operating As Sa Pathology Crystalline composition of GM-CSF/GM-CSFR
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2011029126A1 (en) * 2009-09-14 2011-03-17 Walter And Eliza Hall Institute Of Medical Research Methods and reagents for producing antibodies against autoantigens
BR112013006718B1 (pt) * 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo

Also Published As

Publication number Publication date
AU2019236675A1 (en) 2019-10-17
JP6475166B2 (ja) 2019-02-27
US9861688B2 (en) 2018-01-09
AU2019236675B2 (en) 2022-02-24
AU2013357239B2 (en) 2019-10-17
ES2721159T3 (es) 2019-07-29
EP2932264B1 (en) 2019-01-30
JP2016501268A (ja) 2016-01-18
TR201905447T4 (tr) 2019-05-21
US20180099033A1 (en) 2018-04-12
AU2013357239A1 (en) 2015-06-18
WO2014091034A1 (en) 2014-06-19
PT2932264T (pt) 2019-05-21
SI2932264T1 (sl) 2019-05-31
US10987413B2 (en) 2021-04-27
CA3108192A1 (en) 2014-06-19
EP2932264A1 (en) 2015-10-21
DK2932264T3 (da) 2019-05-06
CA2894966C (en) 2021-03-30
HUE042967T2 (hu) 2019-07-29
US20150313978A1 (en) 2015-11-05
CA2894966A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
ZA201407509B (en) Anti-fcrn antibodies
PL3117837T3 (pl) Formulacje przeciwciała
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
SG10201709290XA (en) Anti-H7cr Antibodies
IL234883A0 (en) CDR-modified anti-siglac-15 antibody
HUE042967T2 (hu) Új, MHC-tõl független tumorasszociált antigének
GB201220242D0 (en) Antibody
EP2804876A4 (en) NEW ANTIBODIES
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies